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Strengths and limitations of this study
 ► In the present randomised, controlled clinical, an in-
tegrative e- health and m- health solution for chronic 
pain management is implemented.
 ► Patient monitoring is performed remotely in an eco-
logical and momentary manner with a smartphone 
app.
 ► Patient responses to the app might generate alarms 
in the presence of unwanted clinical events.
 ► Physicians can track patient evolution at any time on 
a website and receive clinical alarms daily.
 ► Study limitations include the fact that physicians are 
not blinded to the patients’ condition and the rigidity 
of the app assessment protocol.
AbStrACt
Introduction Chronic pain has become a matter of public 
health concern due to its high prevalence and because 
public costs associated with treatment and disability 
increase each year. Research suggests that limitations 
in the traditional assessment of chronic pain patients 
limit the effectiveness of current medical treatments. The 
use of technology might serve change patient traditional 
monitoring into ecological momentary assessments, which 
might be visualised by physicians live. This study describes 
a randomised control trial designed to test the utility 
of a technology- based solution for pain telemonitoring 
consisting of a smartphone app for patients and a web 
application for physicians. The goal of this study will be to 
explore whether this combination of eHealth and mHealth 
improves the effectiveness of existing pain treatments.
Methods and analysis Participants will be 250 patients 
randomly assigned to one of these two conditions: 
treatment- as- usual (TAU) and TAU +app+ web. All 
participants will receive the usual treatment for their pain. 
Only the TAU +app+ web group use Pain Monitor app, 
which generates alarms that are sent to the physicians 
in the face of previously established undesired events. 
Physicians will be able to monitor app reports using a 
web application, which might result in an adjustment 
of treatment. We anticipate that the use of Pain Monitor 
plus the therapist web will result in a reduction of pain 
intensity and side effects of the medication. Improvements 
on secondary outcomes, namely fatigue, mood, pain 
interference, rescue medication use and quality of life, 
are also expected. Mixed repeated- measure multivariate 
analyses of variances will be conducted to investigate 
whether there are differences between preassessment and 
postassessment scores as a function of the experimental 
condition.
Ethics and dissemination Ethical approval from the 
Hospital General Universitari de Castellon was obtained. 
The findings will be published in peer- reviewed journals.
trial registration number NCT03606265
IntroduCtIon
Pain can be defined as ‘an unpleasant 
sensory and emotional experience associated 
with actual or potential tissue damage, or 
described in terms of such damage’1 and can 
only be understood as an interplay between 
‘sensory, emotional, cognitive and social 
components’.2 Although pain often is acute 
and disappears as tissues heal, sometimes pain 
persists for long periods of time and becomes 
chronic. For instance, it has been reported 
that 15% of individuals admitted to trauma 
hospitals due to a severe injury and 15%–60% 
of patients after surgery will continue to expe-
rience chronic pain months and years later.3 
In general, a cut- off of 3–6 months is used to 
define the transition from acute/subacute to 
chronic pain.4
The aforementioned chronification of 
pain is becoming a major public health 
problem across the globe.5 We refer here 
to primary chronic pain, a pain associated 
with important interference on functioning 
and/or emotional distress, which cannot be 
better accounted for by any other condition.6 
Specifically, epidemiological studies indicate 
that the prevalence of this disease in the adult 
population ranges from 19% to 38% world-
wide.7–10 Furthermore, the increase in life 
expectancy and the ageing of the population 
is likely to have an important impact on the 
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number of individuals experiencing chronic pain, since 
the prevalence of this syndrome boosts dramatically with 
age.11 For instance, it is expected that the population 
of chronic pain individuals will be doubled in 2050 for 
people older than 65 years and tripled for people over 80 
years of age.12 Thus, chronic pain is a major public health 
challenge due to its high prevalence in the population 
and high direct and indirect costs for the institutions and 
the individuals.13 14
Indeed, chronic primary pain (eg, fibromyalgia or non- 
specific low back or neck pain, to name some examples) 
is imposing a huge burden in our societies as this disease 
has become one of the leading causes of years lived with 
disability globally.15 16 Not surprisingly, as a result of the 
growing concern about this disease, there have been 
numerous attempts to improve treatments for pain in 
the past decades. However, recent reviews on the effec-
tiveness of numerous interventions, including medical 
treatments, psychological therapy, physical rehabilitation 
or a combination of these, indicate that the effectiveness 
of existing treatments is, on average, only modest.17–19 
While there might be numerous factors explaining the 
limited effectiveness of current interventions for pain, 
including unexplored biomechanical mechanisms or 
genetic factors, patient characteristics or therapists’ 
training, some authors have pointed to methodological 
shortcomings as key elements explaining the modest 
effectiveness of pain interventions. Specifically, the way 
assessment is currently performed (ie, a single measure 
of pain intensity performed episodically during the onsite 
appointments) has been argued to impact negatively in 
the ability of existing interventions to achieve more reli-
able and powerful changes in patient outcomes.20 21 For 
instance, a single rate of pain intensity has been shown to 
be an unreliable measure of pain as this experience can 
vary dramatically within the same day and across days.22–24 
In addition, pain is frequently assessed retrospectively, 
which is known to lead to recall bias and to decrease the 
accuracy of pain ratings25 and does not allow for timely 
responses to undesired events, so these often take place 
time after the problem occurred.21
As a consequence of the above, ecological momentary 
assessment (EMA), which refers to the assessment of pain 
repeatedly and in real life, has received renewed interest 
in the past years in the pain literature and is now consid-
ered by many as the gold standard method to assess the 
pain experience.26–29 Traditionally, EMA has been difficult 
due to the limitations and costs of repeated measurement 
procedures (ie, paper diaries or phone calls). However, 
with the explosion and availability of smartphones, EMA 
has become easier than ever and immediate communica-
tion between the patient and the physician is now a more 
feasible practice.30
It has been argued that this change in the assessment 
paradigm towards ecological daily telemonitoring using 
apps will improve treatment effectiveness and reduce costs 
if used to respond to patient reports quickly.21 31 Indeed, 
there is evidence to suggest that smartphones are useful 
tools to be used for the assessment of pain core outcome 
measures in chronic pain settings.21 32 33 However, the 
extent to which this EMA of pain patients can effectively 
lead to better practices in pain medicine is still unknown. 
For this purpose, we developed a technology- based solu-
tion that integrated a pain and symptom tracking app for 
patients and a web for physicians where app- generated 
alarms are received daily and patient app responses can 
be monitored in real time.
With the previous goal in mind, in the present parallel 
group, superiority trial we will use the Pain Monitor app 
(https:// play. google. com/ store/ apps/ details? id= pain-
monitor. srccode), which was developed by a team of 
psychologists and an engineer with the collaboration of 
physicians and nurses and has been recently validated 
in clinical settings,21 together with a web for the physi-
cians where app responses and alarms can be tracked in 
real time to facilitate the professional’s decision- making 
process. As we will explain in more detail in the Methods 
section, Pain Monitor assesses a number of pain- related 
outcomes (ie, pain intensity, pain interference, anxiety 
and depression and use of pain- related health resources) 
and the most frequent side effects of medical treatments 
for pain. In the study, patients will be randomly assigned 
to a treatment- as- usual condition (TAU) or to a TAU with 
the support of the patients’ app and the physician’s web. 
We anticipate that the use of the web application linked 
with the smartphone app (TAU +app+ web condition) will 
improve the effectiveness of usual treatments resulting in 
reduced pain intensity and less frequent side effects of the 
medication after 1 month of medical treatment. Addition-
ally, we expect that this group of patients will present addi-
tional improvements on secondary outcomes, including 
mood (depression and anxiety), pain interference, pain 
catastrophising and use of pain- related health resources 
in the past month as secondary gains of reducing pain 
levels, as suggested in the literature.34 We also expect that 
the rapid detection of treatment undesired events will 
rapidly minimise threats to the patient’s quality of life and 
mood.
MEthod
Study design
The current investigation is a randomised superiority 
clinical trial composed of two parallel groups (1:1 alloca-
tion ratio): (1) TAU and (2) TAU +app+ web. In the study, 
participants in the TAU condition receive the usual pain 
treatment by the physicians working at the pain unit (ie, 
pharmacological treatment or infiltration). Participants 
included in TAU +app+ web group receive the usual treat-
ment for their pain plus daily monitoring of their symp-
toms and pain experience with the Pain Monitor app 
during 1 month. In the TAU +app+ web condition, alarms 
are generated in the presence of previously established 
undesired events, which have been previously determined 
by the physicians at the pain clinic (eg, pain intensity is 
higher than 7 in an 11- point numerical scale during three 
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Figure 1 Study schedule of enrolment, interventions and 
assessments.
box 1 Inclusion criteria
 ► The patient is over 18 years of age.
 ► The patient has a mobile phone with Android operating system (the 
app is currently only available for Android, which is the operating 
system used by more than 80% of users in Spain).49
 ► The patient has the physical ability to use the application.
 ► A new treatment plan is started during the first week after study 
onset.
 ► The patient does not present psychological and/or cognitive alter-
ations or problems with language that make his/her participation 
difficult.
 ► The patient voluntarily wants to participate and signs the informed 
consent form.
consecutive days). Physicians are able to monitor these 
patients’ app reports using a web application created 
for this purpose (https:// monitordolor. dolortic. com/). 
Thus, phone calls can be conducted in the presence of 
alarms in order to change or discontinue the medical 
treatment when necessary. If the study results indicate 
that the use of technology leads to better outcomes, 
participants in the TAU condition will be informed about 
these findings and will be offered the possibility to use the 
app after study participation. In the TAU condition only, 
assessment is performed as usual, that is, using self- report 
measures administered onsite at the beginning and the 
end of the study (1 month later).
Neither the physicians nor the patients will be blind to 
the treatment condition assigned.
Physicians will not be blind because they will receive 
alarms from the TAU +app+ web participants only. 
Patients will not be blind because only those in the TAU 
+app+ web condition will be using technology in addi-
tion to usual treatment and because patients in the TAU 
condition must know that there is no telemonitoring in 
their condition.
All items from WHO Trial Registration Data Set are 
showed in the online supplementary file 1. The recruit-
ment started at the end of the same month. Standard 
Protocol Items: Recommendations for Interventional 
Trials guidelines were followed to design the trial. The 
participant timeline (ie, schedule of enrolment, interven-
tions and assessments) is shown in figure 1. Recruitment 
is currently ongoing and is expected to end in November 
2019.
Sample
Participants will be 250 consecutive chronic pain patients 
attending the pain clinic at the Hospital General Univer-
sitari de Castello (Spain) for the first time. Required 
sample size was calculated using G*Power.35 Although 
the a priori calculation resulted in 198 participants, the 
sample size was increased to 250 considering a drop- out 
rate of 27%–30% based on previous studies.36 37 Thus, 125 
participants were assigned to each condition. Randomis-
ation of participants was performed by an independent 
researcher using a computer- generated sequence with 
Randomizer.38 Inclusion criteria are shown in box 1. Only 
patients for whom a change in the treatment is planned 
(eg, an epidural infiltration or a change in the prescribed 
medication) will be included in the study (this includes 
both new and consecutive patients). The reason for 
doing this is that the utility of the technology is expected 
to be maximised during the onset of new treatments, as 
opposed to those cases in which the treatment plan is 
already well established.
In the study, all participants are identified using an 
alphanumeric code. In the case of participants in the 
TAU +app+ web condition, this code is automatically 
generated by the app. Thus, the database generated 
by the app is anonymised and the app only collects the 
international mobile equipment identity. The association 
between app codes and patient identifiable character-
istics is stored locally at the pain clinic. All data storage 
procedures follow the European law and data protection 
rules (European Union General Data Protection Regu-
lation 2016/679 of the European Parliament and of the 
Council of 27 April 2016). Important protocol modifi-
cations will be notified and require the approval of the 
Ethics Committee of the Hospital General Universitari 
de Castello. Approved changes will be made public at 
ClinicalTrials. gov. All the participants read and sign an 
informed consent form before randomisation (see online 
Protected by copyright.
 o
n
 January 24, 2020 at Universidad de Zaragoza. Biblioteca.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033586 on 29 December 2019. Downloaded from 
4 Jaén I, et al. BMJ Open 2019;9:e033586. doi:10.1136/bmjopen-2019-033586
Open access 
Figure 2 (A) Pain monitor instructions; (B) pain monitor assessment of pain intensity; (C) pain monitor assessment of fatigue.
supplementary file 2). Patients, who do not agree with the 
assigned condition, are given the opportunity to be allo-
cated to the preferred condition, but are not used in the 
analyses. Any changes to modify the assigned condition 
are accepted at any time during the study, again resulting 
in an exclusion from the study. Changes in the medica-
tion or improvement of disease do not result in study 
discontinuation. Disease worsening is not expected to be 
associated with the inclusion of the app but, if existent, 
will result in the discontinuation of app use.
Procedure
The study is conducted at the pain clinic of the Hospital 
General Universitari de Castelló. The study is advertised 
by the physicians to all consecutive patients attending 
the pain clinic for the first time. To ensure enrolment, 
physicians will emphasise the importance of active 
patient participation in research in general and in self- 
monitoring in particular. Patients interested in partic-
ipating are directed to another office where the lead 
author, IJ, explains the study procedures in more detail 
and ensures their eligibility. IJ is in charge of increasing 
adherence to the treatment (ie, app) by explaining the 
utility of the study and by contacting patients when an 
alarm informing of low app adherence (ie, more than 
three consecutive days without response) is received. All 
participants are provided with an information sheet and 
sign the informed consent. After participation accep-
tance, participants are assigned to one of the experi-
mental conditions (TAU or TAU +app+ web), which had 
been previously randomised by an external researcher. All 
participants then complete a paper- and- pencil assessment 
protocol in order to control for differences between the 
two assessment formats (app vs pen and pencil) and to 
compare both conditions using the same assessment 
approach. In addition to this paper- and- pencil evalua-
tion, patients in the TAU +app+ web condition download 
and instal the Pain Monitor app into their phones. Once 
they instal the app, they answer to an initial assessment 
and then complete two measures daily (10:00 and 19:00 
hours) during 1- month (study duration). Finally, an end 
of study appointment is set (1 month later) to conduct 
the postassessment evaluation. Due to difficulties in trans-
portation or availability, the postassessment intervention 
can either be completed onsite or via an on- line survey.
Pain monitor
The Pain Monitor app (figure 2) has been developed by 
a group of pain psychologists and an engineer, with the 
collaboration of physicians and nurses specialised in pain 
care. Pain Monitor is composed of several pain- related 
items which are to be answered twice a day at preset times 
(10:00 am and 19:00 hours, with a 2- hour flexibility) 
during 30 days. The app content has been previously 
validated with chronic pain patients at the pain unit of 
the Vall d’Hebron Hospital.21 This assessment protocol 
contains sociodemographic items (ie, age, sex and educa-
tion level, among others) which are evaluated on the first 
day of app use only, as well as a number of pain- related 
outcomes that are evaluated daily, which have been 
selected following recent guidelines on core outcome 
domains for pain treatments.39 40 Constructs in the app, 
including pain intensity, pain interference, anxiety, 
depression, catastrophising, social support, acceptance 
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and coping, among others, are measured with a single 
item to reduce the burden of daily assessment, each of 
which was adapted and validated against well- established 
paper- and- pencil measures.21 Additionally, the assess-
ment protocol includes a list of side effects created ad 
hoc based on the literature findings on the most frequent 
adverse effects of pain treatments,41 42 as well as measures 
of treatment adherence, use of rescue medication, neuro-
pathic characteristics of pain and use of medical services 
in the past month. All app items can be found in online 
supplementary file 3.
The app generates alarms in the presence of predefined 
events (see online supplementary file 4 for the alarms 
set in the present study in collaboration with the partic-
ipating physicians). These alarms are sent to the physi-
cians early in the morning on working days so that they 
can decide whether an action from their side is required 
(eg, calling the patient and setting an earlier appoint-
ment or suggesting a change in the medication). For 
this study, a website linked to the app was created for the 
physicians to observe patient alarms and evolution live. 
Examples of the physician web are presented in figure 3. 
Physicians are only asked to check the website when an 
alarm happens, but they are allowed to check any patient 
status at any time.
Interventions
Five physicians at the pain clinic of the Hospital General 
Universitari de Castelló participate in this study. All 
patients in the study receive the usual treatment for their 
pain irrespective of their assigned condition. However, a 
change in treatment might occur in the TAU +app+ web 
condition at the discretion of the physicians in charge 
of treatment after receiving an alarm and consulting the 
web page with the graphical representation of patient app 
responses. As usual, patients in the TAU condition without 
the app are not contacted by the physicians between 
appointments. It is important to note that both patients 
in the TAU only and patients in the TAU +app+ web 
condition are allowed to attend to the emergency services 
or the family physician in the event of an emergency at 
any stage of the study due to ethical reasons. At the end of 
the study, this practice is investigated for each participant 
in the final assessment.
Assessment plan
All participants in the study fill in a number of question-
naires in a paper- and- pencil format at the beginning 
and at the end of the study. This assessment protocol 
includes sociodemographic information, sickness work 
absence during the past month, use of pain- related health 
resources in the past month (ie, emergency services, 
family physician or pain clinic), pain- related physical 
symptoms experienced in the past week (ie, side medica-
tion effects), the Brief Pain Inventory (pain severity and 
interference),43 the Pain Catastrophising Scale44 and the 
Hospital Anxiety and Depression Scale.45 In addition to 
this paper- and- pencil evaluation, participants in the TAU 
+app+ web condition also instal the Pain Monitor app and 
complete a preintervention assessment in the app after 
the paper- and- pencil evaluation. Both baseline assess-
ments include the same content and are duplicated to 
provide further evidence for the validity of app content. 
After this pretreatment evaluation, participants in the 
TAU +app+ web group are asked to answer to the app 
assessments twice a day during 1- month (study duration). 
A push- up system notifies the patient about the need to 
respond to the app evaluation at 10:00 and 19:00hours. 
These times can be adjusted by the patient with a 2- hour 
flexibility from the preset times.
Daily morning and evening assessments differ in a 
number of items. Some items are asked twice a day (ie, 
pain intensity, sadness, anxiety), while others are only 
administered in the morning (eg, interference of pain on 
sleep) or in the evening (eg, activity level during the day, 
interference of pain on daily activities, or physical symp-
toms experienced during the day).
Finally, 30 days after the treatment onset (ie, first evalu-
ation), both groups complete a postassessment protocol. 
The measures included in this final evaluation are similar 
to the ones included in the baseline assessment, with the 
inclusion of a measure of negative events experienced 
during the study period and the evaluation of perceived 
change due to treatment.
In the study, primary outcomes are pain intensity and 
the number of side effects of the medication reported 
in the app, while secondary outcomes include mood 
(depression and anxiety), pain interference, pain cata-
strophising and use of pain- related health resources in 
the past month.
Note that app reports in the TAU +app+ web condi-
tion are not used to determine treatment effectiveness 
compared with the TAU only condition because in the 
latter condition participants do not use the app. There-
fore, app responses are only used for telemonitoring and 
early detection of treatment problems that result in an 
alarm to the physicians. The comparison of both condi-
tions will be made using the traditional paper- and- pencil 
evaluations, which will be available for both groups. 
Additionally, the number of alarms and the physician’s 
responses to such alarms (eg, change in treatment strat-
egies) will be registered. This information will be used to 
get better insight into the utility of the integrated tech-
nology to improve treatment efficacy.
Patient and public involvement
In the current study, patients or the public will not be 
involved in the design, or conduct, or dissemination of 
the research.
data analysis
The aim of the present study is to explore the effect of 
an integrated technology- based solution for chronic pain 
monitoring (an app that monitors pain patients daily and 
sends clinical alarms to physicians and a web for physicians 
that graphically represents patient evolution as reported 
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Figure 3 Examples of the web for the physician. (A) Patient’s side effects during 30 days. (B) Patient morning values on pain, 
fatigue and Interference on sleep. (C) Distribution of patient side effects.
in the app) compared with the usual treatment where 
monitoring is made using a paper- and- pencil, episodic, 
onsite evaluation. With this aim in mind and completer 
analyses will be performed following the recommenda-
tions of the Consolidated Standards of Reporting Trials 
guidelines (http://www. consort- statement. org/). First, 
the two conditions will be compared at baseline in the 
different continuous measures with a between- group 
analysis via a t- test to ensure that randomisation indeed 
resulted in comparable groups prior to intervention. X2 
tests will be used for all the categorical variables. To eval-
uate our hypothesis, mixed repeated- measure multivar-
iate analyses of variances (MANOVAs) will be conducted 
to investigate whether there are differences between 
preassessment and postassessment scores as a function of 
the experimental condition (TAU or TAU +app+ web). 
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Distribution normality and homoscedasticity assump-
tions will be tested by means of Kolmogorov- Smirnov and 
and Levene tests, respectively, and a Mann- Whitney U 
test and Brown- Forsythe F- test will be used where neces-
sary. Effect size will be calculated to complement the 
MANOVA results with the standardised mean difference 
(Cohen’s d) for both between and within group analyses. 
This is a novel study and effect sizes are difficult to antic-
ipate. However, we expect to find larger (ie, moderate) 
between- groups effect sizes for primary outcomes (ie, 
pain intensity and number of side effects of the medi-
cation) when compared with secondary outcomes since 
medical interventions do not specifically focus on these 
symptoms (ie, pain interference, mood, fatigue, rescue 
meditation use and quality of life). The analysis will be 
performed by CS- R, who will be blinded to the treatment 
allocation. Only the present study authors will have access 
to the final trial dataset.
Regarding dropouts, we will choose a strict crite-
rion and the analyses will only include participants who 
complete both the pre and the postassessments. Because 
of the short duration of the trial (1 month per patient) 
and the minimal risks expected from the use of the app, a 
data monitoring committee will not be required. Despite 
the previous, an alarm has been set so that the physi-
cians are warned if a patient fails to respond to the App 
during three consecutive days (ie, an indirect measure 
of potential dropouts attributable to the App use). If this 
happens, the physicians will call the patient and explore 
the reasons for discontinuation and try to obtain a post- 
treatment assessment to reduce bias.
dISCuSSIon
Pain assessment is a complex process characterised by a 
high variability between and within days, which is usually 
performed by clinicians using self- report, onsite, single 
ratings which are based on recall.46 47 EMA using smart-
phone apps appears to be an innovative and promising 
alternative to these traditional assessment methods48 
as smartphone apps have demonstrated to be accurate 
tools to assess pain intensity and related variables from 
the patients’ home, thus facilitating telemonitoring and 
contributing to the personalisation of medical interven-
tions by rapidly adjusting treatments to every individual 
as a result of telemonitoring.25
In the present study protocol, we describe a randomised 
controlled trial designed to test an integrative technology- 
based solution for chronic pain monitoring consisting of 
a web application for the healthcare professional, which 
is linked to the patient’s app (ie, Pain Monitor). Specifi-
cally, we want to explore whether the use of this integra-
tive technology improves the effectiveness of the usual 
treatment for this population thanks to telemonitoring 
and the rapid detection of unwanted events. We expect 
that the use of Pain monitor, with the support of thera-
pist’s web, will result in reduced pain intensity and less 
frequent side effects of the medication after 1 month of 
medical treatment due to the professional’s rapid reac-
tion in the presence of undesired outcomes. Note that 
the study goal is not the explore the feasibility of imple-
menting the use of the integrative technology for patient 
long- term use, but to explore its utility and acceptability 
when used in the short term (eg, during a month) in a 
critical treatment stage (ie, after the onset of a new treat-
ment plan, when pain is not well controlled and treat-
ment tolerance is unclear).
To our knowledge, this is the first study to assess the 
effectiveness of this type of integrative technology solution 
(ie, a therapist web site linked to a patient smartphone 
app) for the telemonitoring of patient symptomatology 
in chronic pain. If our hypothesis is confirmed, our find-
ings will serve to demonstrate the feasibility and utility of 
smartphones and specialised webs for therapists so that 
they can be implemented in specialised care contexts (ie, 
pain clinics). Likewise, our results will provide important 
information about the potential benefits of smartphone 
apps for the personalisation of pain treatments (ie, treat-
ment can be rapidly personalised to a given patient as a 
function of individual responses reported in the app). 
Ultimately, this might help change the model of care for 
this chronic disease (ie, episodic, onsite assessment and 
treatment), since the use of this integrative technology 
system allows for a continuous and remote evaluation and 
intervention, providing a faster response to the patient 
needs and improving self- management and empower-
ment of patients who attend pain clinics as they become 
important agents of treatment effectiveness by being in 
charge of daily reporting of pain- related experiences in 
the app. In sum, the results of the present investigation 
could serve an important first step towards the implemen-
tation of apps and other Information and Communica-
tion Technologies in health services.
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